Heid I, Trajkovic-Arsic M, Lohoefer F, Kaissis G, Harder FN, Mayer M, Topping GJ, Jungmann F, Crone B, Wildgruber M, Karst U, Liotta L, Alguel H, Yen HY, Steiger K, Weichert W, Siveke JT, Makowski MR, Braren RF (2022)
Publication Type: Journal article
Publication year: 2022
Book Volume: 50
Pages Range: 115-129
Journal Issue: 1
DOI: 10.1007/s00259-022-05930-6
Purpose: Pancreatic ductal adenocarcinoma (PDAC) is a molecularly heterogeneous tumor entity with no clinically established imaging biomarkers. We hypothesize that tumor morphology and physiology, including vascularity and perfusion, show variations that can be detected by differences in contrast agent (CA) accumulation measured non-invasively. This work seeks to establish imaging biomarkers for tumor stratification and therapy response monitoring in PDAC, based on this hypothesis. Methods and materials: Regional CA accumulation in PDAC was correlated with tumor vascularization, stroma content, and tumor cellularity in murine and human subjects. Changes in CA distribution in response to gemcitabine (GEM) were monitored longitudinally with computed tomography (CT) Hounsfield Units ratio (HUr) of tumor to the aorta or with magnetic resonance imaging (MRI) ΔR
APA:
Heid, I., Trajkovic-Arsic, M., Lohoefer, F., Kaissis, G., Harder, F.N., Mayer, M.,... Braren, R.F. (2022). Functional biomarkers derived from computed tomography and magnetic resonance imaging differentiate PDAC subgroups and reveal gemcitabine-induced hypo-vascularization. European Journal of Nuclear Medicine and Molecular Imaging, 50(1), 115-129. https://doi.org/10.1007/s00259-022-05930-6
MLA:
Heid, Irina, et al. "Functional biomarkers derived from computed tomography and magnetic resonance imaging differentiate PDAC subgroups and reveal gemcitabine-induced hypo-vascularization." European Journal of Nuclear Medicine and Molecular Imaging 50.1 (2022): 115-129.
BibTeX: Download